Q1 2027 Petmed Express Inc Earnings Call Transcript
Key Points
- Net loss narrowed significantly to $6.1 million from $34.2 million year-over-year, driven by cost discipline and absence of goodwill impairment.
- Recurring net sales (AutoShip and membership) grew to 61.5% of total gross sales, up from 57.6% a year ago, showing strong subscription-driven customer base.
- Customer acquisition improved: acquired ~70,000 new customers in Q1, with cost per new customer down 15% to $60 from $71.
- Launched first white-label pharmacy partnership with Rural King, expanding customer reach and creating new revenue streams.
- Completed SAP ERP system rollout and new call center platform, modernizing technology infrastructure for scalability and efficiency.
- Entered new freight agreement providing faster deliveries (up to two days faster to West Coast), enhancing customer experience and retention.
- Announced sale-leaseback of headquarters and distribution center for $37 million, strengthening balance sheet and providing financial flexibility.
- Net sales declined 19.9% year-over-year to $41 million, reflecting continued softness in prescription medication sales.
- Gross profit margin decreased to 27.6% from 28.1%, due to lower manufacturer rebates as a percentage of sales.
- Adjusted EBITDA loss widened to $3.4 million from $2.7 million in the prior year.
- Company still operating at a net loss, with no clear timeline for returning to sustainable profitability.
- Intense competition in the direct-to-consumer pet health landscape persists, pressuring revenue growth.
- Uncertainty regarding SilverCape Investments' unsolicited acquisition proposal, creating potential distraction and strategic ambiguity.
- CEO search remains ongoing, with interim leadership in place, which may hinder long-term strategic execution.
Greetings, and welcome to the PetMed Express, Inc. Q1 2027 earnings results conference call. (Operator Instructions) It is now my pleasure to introduce your host, Reed Anderson with ICR. You may begin.
Thank you, and welcome to the PetMed Express fiscal first quarter 2027 earnings conference call. With us on the call today are Leslie Campbell, PetMeds' Chairman and Interim CEO and President, and Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer.
Certain information included during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934, as amended, that may involve a number of risks and uncertainties. These statements are based on our beliefs as well as assumptions we've used based upon information currently available to us.
Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
